Cellectar biosciences to highlight 2025 strategic initiatives at upcoming biotech showcase during the jp morgan healthcare conference

Oral presentation presented at ash 2024 showed iopofosine i 131 achieved an 83.6% orr and exceeded primary and secondary efficacy endpoints in phase 2 clover-wam study for relapsed/refractory waldenstrom's macroglobulinemia

CLRB Ratings Summary

CLRB Quant Ranking